CGRP monoclonal antibody fremanezumab may reduce weather-triggered migraine attacks, study finds
By
Tara Haelle
Summary
A post hoc analysis of pooled data from two clinical trials found that the CGRP monoclonal antibody fremanezumab reduces the risk of weather-related migraine attacks in patients with episodic migraine. This is reportedly the first study to show that any preventive drug can help with weather-associated headaches, offering hope that preventive treatment may blunt the impact of weather-related migraine triggers.
Source
Key quotes
· 2 pulledThis is actually the very first study to show that any preventive drug can help weather-associated headache.
Preventive treatment may blunt the impact of weather-related migraine triggers, in what investigators say is a first for migraine prevention.
You might also wanna read
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl

Microvascular hypoxia and inflammation as unified drivers of chronic pain syndromes
This opinion article proposes that compromised microvascular perfusion (capillary constriction, hypoxia) and inflammation are fundamental, i
Diagnosed with Anti-NMDA Receptor Encephalitis: A Personal Health Update
Andrew Gallant (creator of ripgrep) shares his recent diagnosis of anti-NMDA receptor encephalitis, an autoimmune disorder causing brain inf

Nature Medicine retracts study claiming morning immunotherapy improves lung cancer outcomes
Nature Medicine has retracted a high-profile clinical trial paper that claimed lung cancer patients receiving immunotherapy in the morning h
Checking your browser - reCAPTCHA
Cuatro comunidades autónomas españolas sufrirán un aumento de más de 10°C la próxima semana por la dorsal subtropical
Un artículo meteorológico que informa sobre el regreso de la dorsal subtropical a España, provocando un aumento extraordinario de temperatur

Comments
Sign in to join the conversation.
No comments yet. Be the first.